Research Article
SLC2A9 Gene Polymorphism Is Associated with Elevated Serum Uric Acid Caused by Pyrazinamide
Table 4
Haplotype analysis of SLC2A9, SLC22A12, and ABCG2 genes between groups.
| | Haplotype | Low-risk group (n = 60) | High-risk group (n = 83) | value |
| | SLC2A9 (rs1014290–rs13129697) | AT | 53 (44.17%) | 105 (63.25%) | — | | GG | 53 (44.17%) | 45 (27.11%) | | | AG | 9 (7.50%) | 15 (9.04%) | 0.485 | | GT | 5 (4.17%) | 1 (0.60%) | 0.071 |
| | SLC22A12 (rs3825016–rs475688–rs893006) | CTC | 65 (54.17%) | 99 (59.64%) | — | | TCA | 29 (24.17%) | 38 (22.89%) | 0.631 | | CCC | 26 (21.67%) | 29 (17.47%) | 0.409 |
| | SLC22A12 (rs7929627–rs893006) | AC | 46 (38.33%) | 67 (40.36%) | — | | GC | 45 (37.50%) | 61 (36.75%) | 0.945 | | AA | 29 (24.17%) | 35 (21.08%) | 0.971 | | GA | 0 (0.00%) | 3 (1.81%) | 0.991 |
| | ABCG2 (rs2054576–rs2231142–rs3114018) | AGC | 47 (39.17%) | 53 (31.93%) | — | | AGA | 41 (34.17%) | 62 (37.35%) | 0.589 | | GTC | 21 (17.50%) | 32 (19.28%) | 0.344 | | ATC | 6 (5.00%) | 17 (10.24%) | 0.052 | | GGA | 3 (2.50%) | 2 (1.20%) | 0.646 | | ATA | 2 (1.67%) | 0 (0.00%) | 0.992 |
| | ABCG2 (rs2054576–rs2728109) | AC | 91 (75.83%) | 128 (77.11%) | — | | GA | 21 (17.50%) | 31 (18.67%) | 0.834 | | AA | 5 (4.17%) | 4 (2.41%) | 0.451 | | GC | 3 (2.50%) | 3 (1.81%) | 0.695 |
|
|
The difference was statistically significant. |
